Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects With Moderate-to-severe Atopic Dermatitis

NCT04212169 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04212169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04212169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects With Moderate-to-severe Atopic Dermatitis
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
December 9, 2019
Completion date
September 20, 2022
Enrollment
148 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis